Amgen profits rise, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
FierceBiotech1d
Amgen's early-stage obesity asset slapped with FDA hold
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...
pharmaphorum6d
Amgen's big reveal of obesity data falls a little flat
MariTide (maridebart cafraglutide; previously AMG 133) has emerged as one of Amgen's most promising pipeline projects thanks to its potential to offer once-monthly or even less frequent dosing ...
pharmaphorum2mon
Amgen plays down safety concern with obesity candidate
MariTide (maridebart cafraglutide; formerly AMG 133) hit the headlines in May after Amgen management expressed its excitement about the GLP-1 and GIP-directed bispecific antibody in its first ...
BioSpace19h
Pipeline Problems Mar Amgen’s Q4 Beat
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...
STAT1d
Study of Amgen’s early obesity candidate paused by FDA
The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...
Hosted on MSN2mon
Amgen share price plummets despite Phase II weight loss success
Amgen's share price has dropped despite announcing positive data from its Phase II MariTide (maridebart cafraglutide, formerly AMG 133) study, boasting 20% weight loss. Data from the Phase II ...
Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...
Yahoo Finance9d
Amgen Inc. (AMG.F)
The webcast will be broadcast over the interne Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, ...